Journal article
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxanebased chemotherapy
S Darb-Esfahani, C Denkert, A Stenzinger, C Salat, B Sinn, C Schem, V Endris, P Klare, W Schmitt, JU Blohmer, W Weichert, M Möbs, H Tesch, S Kümmel, P Sinn, C Jackisch, M Dietel, T Reimer, S Loi, M Untch Show all
Oncotarget | IMPACT JOURNALS LLC | Published : 2016
Open access
Abstract
Background: TP53 mutations are frequent in breast cancer, however their clinical relevance in terms of response to chemotherapy is controversial. Methods: 450 pre-therapeutic, formalin-fixed, paraffin-embedded core biopsies from the phase II neoadjuvant GeparSixto trial that included HER2-positive and triple negative breast cancer (TNBC) were subjected to Sanger sequencing of exons 5-8 of the TP53 gene. TP53 status was correlated to response to neoadjuvant anthracycline/taxane-based chemotherapy with or without carboplatin and trastuzumab/lapatinib in HER2-positive and bevacizumab in TNBC. p53 protein expression was evaluated by immunohistochemistry in the TNBC subgroup. Results: Of 450 brea..
View full abstractGrants
Funding Acknowledgements
This translational study was performed within the EU-funded FP7 RESPONSIFY project. The GeparSixto clinical trial was funded by Teva Pharmaceutical Industries Ltd., Glaxo-Smith-Kline, and Roche.